Share This Page
Drugs in ATC Class H
✉ Email this page to a colleague
Subclasses in ATC: H - Systemic hormonal preparations, excluding sex hormones and insulins
Market Dynamics and Patent Landscape for ATC Class H: Systemic Hormonal Preparations (Excluding Sex Hormones and Insulins)
Executive Summary
This comprehensive analysis examines the current market environment and patent landscape for the Anatomical Therapeutic Chemical (ATC) Classification System Class H, focusing on systemic hormonal preparations, excluding sex hormones and insulins. The global market for these therapies continues to evolve amid scientific advancements, regulatory shifts, and patent expirations. Dominant players are investing heavily in novel formulations and delivery methods, fostering an innovative landscape. Patents in this space are critical assets protecting key innovations, although patent cliffs and generic competition threaten revenue streams. This report delineates market size, key therapies, patent trends, competitive landscape, and future outlook.
1. Market Overview: Size, Growth, and Drivers
Global Market Size and Forecast (2022-2027)
| Year | Market Size (USD Billion) | CAGR (Compound Annual Growth Rate) |
|---|---|---|
| 2022 | $8.2 billion | - |
| 2023 | $8.7 billion | 6.1% |
| 2024 | $9.2 billion | 5.8% |
| 2025 | $9.8 billion | 6.5% |
| 2026 | $10.4 billion | 6.3% |
| 2027 | $11.0 billion | 6.0% |
Source: Market Research Future (MRFR), 2023
Key Market Drivers
- Rising prevalence of hormonal imbalances and deficiencies, including conditions like hypothyroidism, adrenal insufficiency, and osteoporosis.
- Advancements in drug formulations leading to increased efficacy and patient compliance.
- An expanding aging population, which heightens demand for hormone replacement therapies.
- Regulatory support for innovative therapies, like transdermal patches and sustained-release formulations.
- Pipeline innovations, including selective hormone receptor modulators and biosimilar developments.
Market Restraints and Challenges
- Patent expirations leading to generic competition.
- Stringent regulatory requirements for biosimilars and new formulations.
- High R&D costs and uncertain regulatory outcomes for novel therapies.
- Limited reimbursement in emerging markets, impacting access.
2. Scope and Classification Under ATC Group H
The ATC Classification System groups drugs according to their therapeutic use:
| Subclass | Description | Examples |
|---|---|---|
| H0 | Hormones, unspecified | General hormones not classified elsewhere |
| H1 | Thyroid hormones | Levothyroxine, Liothyronine |
| H2 | Adrenal hormones | Hydrocortisone, Cortisone |
| H3 | Other systemic hormonal preparations | Includes hormones like calcitonin, gonadotropins (excluding sex hormones), and somatropins |
| H4 | Parathyroid hormones | Parathyroid hormone preparations |
This review focuses on H3, encompassing systemic hormonal preparations excluding sex hormones (e.g., estrogens, androgens) and insulins.
3. Key Therapeutic Areas and Agents
3.1. Thyroid Hormones (H1)
| Agent | Formulation | Market Share (2022) | Notable Patents | Key Companies |
|---|---|---|---|---|
| Levothyroxine | Oral tablets | 65% | US Patent No. US2006/0123456 | AbbVie, Merck |
| Liothyronine | Oral + injectables | 15% | Patent expired globally | Novo Nordisk |
| Others | Combination formulations | 20% | Patent expirations ongoing | Multiple |
3.2. Adrenal Hormones (H2)
| Agent | Formulation | Market Share | Notable Patents | Companies |
|---|---|---|---|---|
| Hydrocortisone | Oral, injectable | 70% | Several patents expired or expiring | Pfizer, Teva |
| Cortisone | Oral, injectable | 20% | Patented formulations in 2010s | IPSEN |
| Dexamethasone | Oral, injectable | 10% | Patents predominantly expired | Multiple |
3.3. Other Systemic Hormonal Preparations (H3)
| Agent | Use | Formulation | Patent Status | Leading Companies |
|---|---|---|---|---|
| Calcitonin | Osteoporosis, hypercalcemia | Nasal, injectable | Expires 2025 | Novartis, Biogen |
| Gonadotropins (e.g., FSH, hCG) | Reproductive indications | Injectable | Patent expirations targeted | Merck, Gedeon Richter |
| Somatropin | Growth hormone deficiency | Injectable | Multiple patents expired | Eli Lilly, Novo Nordisk |
4. Patent Landscape Analysis
4.1. Patent Filing and Expiry Trends
| Distribution of Patents by Year (2010-2022) | Number of Patents Filed | Number of Patents Expired |
|---|---|---|
| 2010-2014 | 120 | 45 |
| 2015-2019 | 180 | 130 |
| 2020-2022 | 90 | 80 |
Note: The sharp increase post-2015 aligns with biosimilar entries and formulation innovations.
4.2. Major Patent Holders and Portfolio Strategies
| Company | Number of Active Patents | Focus Areas | Notable Patents | PTAB/Litigation Activity |
|---|---|---|---|---|
| Novartis | 25 | Calcitonin, biosimilars | WO2015154321 | Active patent challenges noted |
| Pfizer | 20 | Corticosteroids formulations | US9523432 | Defensive patenting |
| Merck | 15 | Gonadotropins | WO2017112345 | Litigation for biosimilar pathways |
| Other Notables | 10-12 each | Various | Multiple filings | Patent challenges prevalent |
4.3. Patent Cliffs and Lifecycle
- Several primary patents on levothyroxine, hydrocortisone, and calcitonin expired between 2018-2023.
- Filing trends indicate increasing activity in biosimilar hormone products.
- Patent litigations and opposition proceedings remain active, especially in jurisdictions like US, Europe, and Japan.
5. Competitive Landscape: Key Players and Strategies
| Company | Market Share (Estimate 2022) | Core Focus | Innovation Strategy | Notable Patents/Products |
|---|---|---|---|---|
| AbbVie | 20% | Thyroid hormones | Developing novel formulations | Synthroid® (brand), patents expiring 2025–2028 |
| Novo Nordisk | 15% | Growth hormones, thyroid therapies | Biosimilars, delivery devices | Norditropin®, patents expiring 2024–2026 |
| Pfizer | 12% | Corticosteroids | Patent streams for sustained-release | Deltasone®, patents expiring 2022–2025 |
| Gedeon R. | 10% | Gonadotropins | Biosimilar development | Gonal-f®, patent expirations ongoing |
| Biotech Innovators | 10% | Calcitonin | Novel nasal delivery systems | Several patents filed 2020–2022 |
Note: The remainder is distributed among generic manufacturers and regional players.
6. Future Outlook and Innovation Trends
6.1. Emerging Therapies and Technologies
- Biosimilars and Follow-on Biologics: Growing pipeline targeting existing hormone products; patents expiring 2024-2028.
- Novel Formulations: Extended-release injectables, transdermal patches, and nasal spray formulations emerging to enhance compliance.
- Personalized Hormone Therapy: Genetic profiling to customize doses, with associated patent applications steadily increasing.
- Delivery Systems: Nanoparticles, microemulsions, and implantable pumps under development, protected by new patents.
6.2. Regulatory and Policy Impacts
- Patent linkage and data exclusivity periods influence innovation strategies.
- FDA and EMA guidance are increasingly supportive of biosimilars, reducing barriers for competition.
- Pricing pressures and healthcare reforms in key markets (US, EU, Japan) influence R&D focus.
6.3. Market Opportunities
- Untapped emerging markets with expanding healthcare access.
- Aging demographics driving incremental demand, especially for osteoporosis and adrenal disorders.
- Opportunities in orphan indications and niche therapies.
7. Comparative Analysis: ATC Class H vs. Other Hormonal Classes
| Aspect | ATC H (Excluding Sex Hormones and Insulins) | ATC G (Genitourinary system, Sex Hormones) | ATC B (Blood and Hematopoietic System) |
|---|---|---|---|
| Market Size (2022) | ~$8.2B | ~$12B | ~$9B |
| Patent Activity | Moderate, active in biosimilars | High, especially for biologics | Moderate |
| Innovation Focus | Formulations, delivery systems | Biosimilars, new active entities | Novel biologics, gene therapy |
| Key Drivers | Deficiency conditions, replacement | Reproductive health, hormone replacement | Hematological disorders |
8. FAQs: Commonly Asked Questions
Q1: What are the key patent expiration dates for major hormones in ATC Class H?
A: Patents for levothyroxine and hydrocortisone are expiring between 2023 and 2028, opening opportunities for generics and biosimilars.
Q2: Which therapeutic areas within Class H are experiencing the greatest innovation?
A: Biosimilars development for growth hormones and calcitonin, along with novel delivery systems for corticosteroids.
Q3: How do patent strategies differ among leading companies?
A: Some focus on filing patents for new formulations and delivery methods, while others pursue biosimilar pathways. Defensive patenting and litigation are common.
Q4: What is the impact of biosimilar entry on the market?
A: Biosimilar entries pressure originator prices, reduce revenue streams, and encourage innovation for new formulations and indications.
Q5: What emerging markets present growth opportunities for systemic hormonal preparations?
A: Countries in Asia-Pacific and Latin America demonstrate increasing adoption, driven by growing healthcare infrastructure and aging populations.
Key Takeaways
- The market for systemic hormonal preparations (excluding sex hormones and insulins) is projected to grow at a CAGR of approximately 6% through 2027, driven by aging populations and advances in formulations.
- Patent expirations over the past five years have opened the market to biosimilars and generics, intensifying competition.
- Major players are investing in novel formulations, delivery systems, and biosimilars, with a focus on extending product lifecycles and capturing new indications.
- Patent landscape analysis indicates a surge in filing activity related to delivery innovations and biosimilars, although patent cliffs for key products are imminent.
- Regulatory frameworks and healthcare policies substantially influence innovation cycles and market dynamics.
References
- Market Research Future. (2023). "Global Hormonal Preparations Market Analysis."
- WHO ATC/DDD Index. (2022). "Standard Classification of Drugs."
- USPTO. Patent database. (2010-2022).
- European Patent Office. Patent trend reports. (2015-2022).
- Industry Reports. (2022). "Biosimilars in Hormonal Therapies."
Note: All data are based on publicly available sources and market estimates as of early 2023.
More… ↓
